- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07950059
Effects of Inulin-Based Prebiotics on Gut Microbiota After Rectal Cancer Surgery (PUMCH-1-YSY)
Effects of Inulin-Based Compound Prebiotics on Postoperative Gut Microbiota Dysbiosis in Patients With Rectal Cancer: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial
Postoperative gut microbiota dysbiosis is a common clinical concern in patients undergoing rectal cancer surgery and may contribute to gastrointestinal dysfunction and postoperative complications. Inulin-based compound prebiotics may help maintain intestinal microbial balance by promoting beneficial bacteria and modulating gut microbial composition. However, their efficacy and safety in preventing postoperative gut microbiota dysbiosis in patients with rectal cancer remain to be established.
This study is a multicenter, randomized, double-blind, placebo-controlled, three-arm clinical trial designed to evaluate the efficacy and safety of inulin-based compound prebiotics in preventing gut microbiota dysbiosis following radical rectal cancer surgery and to assess their effects on gut microbiota composition.
A total of 261 adult patients with histologically confirmed rectal adenocarcinoma undergoing laparoscopic radical rectal cancer surgery with a protective intestinal stoma will be enrolled at three study centers. Eligible participants will be randomly assigned in a 1:1:1 ratio to one of three groups: (1) inulin-based compound prebiotics combined with probiotics, (2) probiotics combined with placebo, or (3) placebo alone. Study interventions will be administered from postoperative day 1 through day 5.
The primary outcome is the incidence of gut microbiota dysbiosis within five days after surgery. Secondary outcomes include changes in gut microbiota composition and diversity, inflammatory markers, and fecal short-chain fatty acid levels. Gut microbiota will be assessed using 16S rRNA gene sequencing and metagenomic sequencing. Safety will be evaluated through the monitoring and recording of adverse events throughout the intervention period.
This study aims to provide clinical evidence regarding the efficacy and safety of inulin-based compound prebiotics for preventing postoperative gut microbiota dysbiosis and their potential role in modulating intestinal microbial homeostasis in patients undergoing rectal cancer surgery.
Studie Overzicht
Toestand
Studietype
Inschrijving (Geschat)
Fase
- Niet toepasbaar
Contacten en locaties
Studiecontact
- Naam: Guole Lin
- Telefoonnummer: 010-13001081483
- E-mail: linguole@126.com
Studie Locaties
-
-
-
Beijing, China, 100730
- Peking Union Medical College Hospital
-
Contact:
- Danyang Zhu
- Telefoonnummer: 010-13466711222
- E-mail: 17710202092@163.com
-
Beijing, China, 100000
- Beijing Friendship Hospital, Capital Medical University
-
Contact:
- Hongwei Yao
- Telefoonnummer: 010-13611015609
- E-mail: yaohongwei@ccmu.edu.cn
-
Beijing, China, 100007
- Beijing Sixth Hospital
-
Contact:
- Yi An
- Telefoonnummer: 010-13621224452
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Adults aged 18 years or older.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-3 before surgery.
- Histologically confirmed rectal adenocarcinoma diagnosed by endoscopic biopsy, with the lower margin of the tumor located ≤12 cm from the anal verge.
- Undergoing laparoscopic radical rectal cancer surgery with a protective intestinal stoma.
- Willing and able to provide written informed consent, understand and comply with study requirements and procedures, and not currently participating in another clinical study considered by the investigator to conflict with this study.
Exclusion Criteria:
- Known intolerance to inulin or prebiotics.
- History of severe irritable bowel syndrome (IBS) or inflammatory bowel disease (IBD).
- Presence of distant metastases, including liver or lung metastases.
- Severe intestinal obstruction, gastrointestinal perforation, gastrointestinal bleeding, or other conditions requiring emergency treatment.
- Undergoing open radical rectal cancer surgery or conversion from laparoscopic to open surgery.
- Use of antibiotics (excluding planned perioperative antibiotic prophylaxis), prebiotics, probiotics, synbiotic products, or immunosuppressive agents within one month before surgery.
- Severe cardiovascular, cerebrovascular, hepatic, renal, pulmonary, or hematopoietic system diseases.
- Pregnant or breastfeeding women.
- Any other condition that, in the investigator's judgment, makes the participant unsuitable for inclusion in the study.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Preventie
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Dubbele
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Inulin-Based Compound Prebiotics Plus Probiotics
Participants in this group will receive oral inulin-based compound prebiotics (4 g twice daily on postoperative day 1, followed by 8 g twice daily on postoperative days 2-5), combined with compound Lactobacillus enteric-coated capsules (0.66 g three times daily) and a triple viable Bifidobacterium preparation (0.42 g three times daily). All interventions will be administered from postoperative day 1 through day 5. |
An oral inulin-based compound prebiotic supplement containing inulin (62.5%), polydextrose (10%), allulose (10%), isomaltooligosaccharides (7.88%), tagatose (7.75%), hyaluronic acid (1.25%), and chitosan oligosaccharides (0.63%). Participants will receive 4 g orally twice daily on postoperative day 1, followed by 8 g orally twice daily on postoperative days 2-5. The intervention will be administered in combination with probiotic preparations in the experimental group. An oral probiotic preparation containing two strains of Lactobacillus rhamnosus and Enterococcus faecium. Participants will receive 0.66 g orally three times daily from postoperative day 1 through day 5. This intervention will be administered in both the inulin-based compound prebiotics plus probiotics group and the probiotics plus placebo group. An oral probiotic preparation containing Bifidobacterium longum, Lactobacillus acidophilus, and Enterococcus faecalis. Participants will receive 0.42 g orally three times daily from postoperative day 1 through day 5. This intervention will be administered in both the inulin-based compound prebiotics plus probiotics group and the probiotics plus placebo group. |
|
Actieve vergelijker: Probiotics Plus Placebo
Participants in this group will receive compound Lactobacillus enteric-coated capsules (0.66 g orally three times daily) and a triple viable Bifidobacterium preparation (0.42 g orally three times daily), combined with maltodextrin placebo administered at the same dosage and schedule as the inulin-based compound prebiotics group. All interventions will be administered from postoperative day 1 through day 5. |
An oral probiotic preparation containing two strains of Lactobacillus rhamnosus and Enterococcus faecium. Participants will receive 0.66 g orally three times daily from postoperative day 1 through day 5. This intervention will be administered in both the inulin-based compound prebiotics plus probiotics group and the probiotics plus placebo group. An oral probiotic preparation containing Bifidobacterium longum, Lactobacillus acidophilus, and Enterococcus faecalis. Participants will receive 0.42 g orally three times daily from postoperative day 1 through day 5. This intervention will be administered in both the inulin-based compound prebiotics plus probiotics group and the probiotics plus placebo group. Maltodextrin will be used as a placebo to match the inulin-based compound prebiotic supplement and probiotic preparations. For the prebiotic-matched placebo, participants will receive 4 g orally twice daily on postoperative day 1, followed by 8 g twice daily on postoperative days 2-5. For the probiotic-matched placebo, participants will receive maltodextrin at doses of 0.66 g and 0.42 g, each administered orally three times daily from postoperative day 1 through day 5. The probiotics plus placebo group will receive the prebiotic-matched placebo, while the placebo comparator group will receive both placebo regimens. |
|
Placebo-vergelijker: Placebo
Participants in this group will receive oral maltodextrin placebo (4 g twice daily on postoperative day 1, followed by 8 g twice daily on postoperative days 2-5), together with additional maltodextrin placebo (0.66 g and 0.42 g, each administered orally three times daily) to match the probiotic preparations used in the other groups. All interventions will be administered from postoperative day 1 through day 5. |
Maltodextrin will be used as a placebo to match the inulin-based compound prebiotic supplement and probiotic preparations. For the prebiotic-matched placebo, participants will receive 4 g orally twice daily on postoperative day 1, followed by 8 g twice daily on postoperative days 2-5. For the probiotic-matched placebo, participants will receive maltodextrin at doses of 0.66 g and 0.42 g, each administered orally three times daily from postoperative day 1 through day 5. The probiotics plus placebo group will receive the prebiotic-matched placebo, while the placebo comparator group will receive both placebo regimens. |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Incidence of Postoperative Gut Microbiota Dysbiosis
Tijdsspanne: Postoperative days 1-5
|
The primary outcome is the proportion of participants who develop gut microbiota dysbiosis within five days following laparoscopic radical rectal cancer surgery with a protective intestinal stoma. Postoperative gut microbiota dysbiosis will be assessed based on clinical manifestations, including abdominal distension, diarrhea or increased stoma output, abdominal pain, fever, nausea, and vomiting, together with relevant laboratory findings. The incidence will be calculated as the number of participants diagnosed with postoperative gut microbiota dysbiosis divided by the total number of participants evaluated in each treatment group, expressed as a percentage. |
Postoperative days 1-5
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Changes in Gut Microbiota Composition and Diversity
Tijdsspanne: Preoperatively and on postoperative days 3 and 5
|
Changes in gut microbiota composition and diversity will be assessed using metagenomic sequencing of fecal samples collected before surgery and during the postoperative period. Gut microbiota composition will be evaluated based on changes in microbial community structure and the relative abundance of bacterial taxa, while microbial diversity will be assessed using diversity indices derived from sequencing data. Changes in gut microbiota composition and diversity will be compared among the three treatment groups. |
Preoperatively and on postoperative days 3 and 5
|
|
Changes in the Bifidobacterium-to-Escherichia coli Ratio (B/E Ratio)
Tijdsspanne: Preoperatively and on postoperative days 3 and 5
|
The Bifidobacterium-to-Escherichia coli ratio (B/E ratio) in fecal samples will be assessed using gut microbiota sequencing data. Changes in the B/E ratio will be compared among the three treatment groups to evaluate alterations in intestinal microbial balance following surgery. |
Preoperatively and on postoperative days 3 and 5
|
|
Serum C-Reactive Protein (CRP) Level
Tijdsspanne: Preoperatively and on postoperative days 3 and 5
|
Serum C-reactive protein (CRP) levels will be measured to assess postoperative inflammatory responses. CRP concentrations will be compared among the three treatment groups. Results will be reported in mg/L. |
Preoperatively and on postoperative days 3 and 5
|
|
Serum Procalcitonin (PCT) Level
Tijdsspanne: Preoperatively and on postoperative days 3 and 5
|
Serum procalcitonin (PCT) levels will be measured as an indicator of postoperative inflammatory responses. PCT concentrations will be compared among the three treatment groups. Results will be reported in ng/mL. |
Preoperatively and on postoperative days 3 and 5
|
|
Serum Interleukin-6 (IL-6) Level
Tijdsspanne: Preoperatively and on postoperative days 3 and 5
|
Serum interleukin-6 (IL-6) levels will be measured to evaluate postoperative inflammatory responses. IL-6 concentrations will be compared among the three treatment groups. Results will be reported in pg/mL. |
Preoperatively and on postoperative days 3 and 5
|
|
Fecal Short-Chain Fatty Acid (SCFA) Levels
Tijdsspanne: Preoperatively and on postoperative days 3 and 5
|
Fecal concentrations of short-chain fatty acids (SCFAs), including acetate, propionate, and butyrate, will be measured to assess gut microbial metabolic activity. Changes in individual SCFA concentrations before and after surgery will be compared among the three treatment groups. |
Preoperatively and on postoperative days 3 and 5
|
Medewerkers en onderzoekers
Studie record data
Bestudeer belangrijke data
Studie start (Geschat)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
- Pathologische processen
- Neoplasmata per site
- Neoplasmata
- Darmziekten
- Gastro-intestinale neoplasmata
- Neoplasmata van het spijsverteringsstelsel
- Ziekten van het spijsverteringsstelsel
- Gastro-intestinale aandoeningen
- Colorectale neoplasmata
- Intestinale neoplasmata
- Rectale ziekten
- Pathologische aandoeningen, tekenen en symptomen
- Rectale neoplasmata
- Postoperatieve complicaties
Andere studie-ID-nummers
- K10393
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
Individual participant data will not be shared with other researchers due to participant privacy and confidentiality considerations and the absence of an approved data-sharing plan.
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .